AstraZeneca Faces Setbacks in Lung Cancer Trials
AstraZeneca said it is ending a late-stage trial that combined one of its key experimental drugs with chemotherapy to treat a certain type of lung cancer, extending a run of setbacks that has deepened scrutiny of the drugmaker’s development pipeline. Investor confidence in the British drugmaker has been dented by a series of blows, including the surprise failure of Wainua…

